Clinical characteristics of patients with ventricular fibrillation during antiarrhythmic drug therapy

J. D. Minardo, J. J. Heger, W. M. Miles, D. P. Zipes, E. N. Prystowsky

Research output: Contribution to journalArticle

114 Citations (Scopus)

Abstract

We retrospectively studied 28 patients with 38 episodes of newly occurring ventricular fibrillation during antiarrhythmic drug therapy. Twenty-six of these patients, who had ventricular fibrillation during single-drug therapy with quinidine, procainamide, or disopyramide, were compared with a control group of 62 patients who had been treated similarly for ventricular arrhythmias but did not have ventricular fibrillation during treatment. The median duration of therapy before ventricular fibrillation was three days. The left ventricular ejection fraction of the study group was lower than that of the control group (0.29 vs. 0.43; P < 0.0001), and concomitant treatment with digitalis and diuretic agents was more common in the study group. The base-line QT interval (corrected for heart rate) was slightly longer in the study group than in the controls (0.47 vs. 0.44; P < 0.005), although both groups had similar degrees of QT prolongation during drug therapy. Four of 13 patients (31 percent) who underwent multiple trials of antiarrhythmic drugs had recurrent episodes of ventricular fibrillation. Six patients died suddenly after a mean follow-up of 18 months - four who were receiving antiarrhythmic therapy and two who were not. We conclude that drug-associated ventricular fibrillation is an early event, that there may be an increased risk of its recurrence with subsequent trials of antiarrhythmic drugs, and that left ventricular dysfunction and concomitant therapy with digitalis and diuretic agents may predispose patients to this complication.

Original languageEnglish
Pages (from-to)257-262
Number of pages6
JournalNew England Journal of Medicine
Volume319
Issue number5
StatePublished - 1988

Fingerprint

Anti-Arrhythmia Agents
Ventricular Fibrillation
Drug Therapy
Digitalis
Diuretics
Control Groups
Disopyramide
Therapeutics
Procainamide
Quinidine
Left Ventricular Dysfunction
Stroke Volume
Cardiac Arrhythmias
Heart Rate
Recurrence
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Minardo, J. D., Heger, J. J., Miles, W. M., Zipes, D. P., & Prystowsky, E. N. (1988). Clinical characteristics of patients with ventricular fibrillation during antiarrhythmic drug therapy. New England Journal of Medicine, 319(5), 257-262.

Clinical characteristics of patients with ventricular fibrillation during antiarrhythmic drug therapy. / Minardo, J. D.; Heger, J. J.; Miles, W. M.; Zipes, D. P.; Prystowsky, E. N.

In: New England Journal of Medicine, Vol. 319, No. 5, 1988, p. 257-262.

Research output: Contribution to journalArticle

Minardo, JD, Heger, JJ, Miles, WM, Zipes, DP & Prystowsky, EN 1988, 'Clinical characteristics of patients with ventricular fibrillation during antiarrhythmic drug therapy', New England Journal of Medicine, vol. 319, no. 5, pp. 257-262.
Minardo, J. D. ; Heger, J. J. ; Miles, W. M. ; Zipes, D. P. ; Prystowsky, E. N. / Clinical characteristics of patients with ventricular fibrillation during antiarrhythmic drug therapy. In: New England Journal of Medicine. 1988 ; Vol. 319, No. 5. pp. 257-262.
@article{7f01a4df12944275819842c95f8b54c9,
title = "Clinical characteristics of patients with ventricular fibrillation during antiarrhythmic drug therapy",
abstract = "We retrospectively studied 28 patients with 38 episodes of newly occurring ventricular fibrillation during antiarrhythmic drug therapy. Twenty-six of these patients, who had ventricular fibrillation during single-drug therapy with quinidine, procainamide, or disopyramide, were compared with a control group of 62 patients who had been treated similarly for ventricular arrhythmias but did not have ventricular fibrillation during treatment. The median duration of therapy before ventricular fibrillation was three days. The left ventricular ejection fraction of the study group was lower than that of the control group (0.29 vs. 0.43; P < 0.0001), and concomitant treatment with digitalis and diuretic agents was more common in the study group. The base-line QT interval (corrected for heart rate) was slightly longer in the study group than in the controls (0.47 vs. 0.44; P < 0.005), although both groups had similar degrees of QT prolongation during drug therapy. Four of 13 patients (31 percent) who underwent multiple trials of antiarrhythmic drugs had recurrent episodes of ventricular fibrillation. Six patients died suddenly after a mean follow-up of 18 months - four who were receiving antiarrhythmic therapy and two who were not. We conclude that drug-associated ventricular fibrillation is an early event, that there may be an increased risk of its recurrence with subsequent trials of antiarrhythmic drugs, and that left ventricular dysfunction and concomitant therapy with digitalis and diuretic agents may predispose patients to this complication.",
author = "Minardo, {J. D.} and Heger, {J. J.} and Miles, {W. M.} and Zipes, {D. P.} and Prystowsky, {E. N.}",
year = "1988",
language = "English",
volume = "319",
pages = "257--262",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "5",

}

TY - JOUR

T1 - Clinical characteristics of patients with ventricular fibrillation during antiarrhythmic drug therapy

AU - Minardo, J. D.

AU - Heger, J. J.

AU - Miles, W. M.

AU - Zipes, D. P.

AU - Prystowsky, E. N.

PY - 1988

Y1 - 1988

N2 - We retrospectively studied 28 patients with 38 episodes of newly occurring ventricular fibrillation during antiarrhythmic drug therapy. Twenty-six of these patients, who had ventricular fibrillation during single-drug therapy with quinidine, procainamide, or disopyramide, were compared with a control group of 62 patients who had been treated similarly for ventricular arrhythmias but did not have ventricular fibrillation during treatment. The median duration of therapy before ventricular fibrillation was three days. The left ventricular ejection fraction of the study group was lower than that of the control group (0.29 vs. 0.43; P < 0.0001), and concomitant treatment with digitalis and diuretic agents was more common in the study group. The base-line QT interval (corrected for heart rate) was slightly longer in the study group than in the controls (0.47 vs. 0.44; P < 0.005), although both groups had similar degrees of QT prolongation during drug therapy. Four of 13 patients (31 percent) who underwent multiple trials of antiarrhythmic drugs had recurrent episodes of ventricular fibrillation. Six patients died suddenly after a mean follow-up of 18 months - four who were receiving antiarrhythmic therapy and two who were not. We conclude that drug-associated ventricular fibrillation is an early event, that there may be an increased risk of its recurrence with subsequent trials of antiarrhythmic drugs, and that left ventricular dysfunction and concomitant therapy with digitalis and diuretic agents may predispose patients to this complication.

AB - We retrospectively studied 28 patients with 38 episodes of newly occurring ventricular fibrillation during antiarrhythmic drug therapy. Twenty-six of these patients, who had ventricular fibrillation during single-drug therapy with quinidine, procainamide, or disopyramide, were compared with a control group of 62 patients who had been treated similarly for ventricular arrhythmias but did not have ventricular fibrillation during treatment. The median duration of therapy before ventricular fibrillation was three days. The left ventricular ejection fraction of the study group was lower than that of the control group (0.29 vs. 0.43; P < 0.0001), and concomitant treatment with digitalis and diuretic agents was more common in the study group. The base-line QT interval (corrected for heart rate) was slightly longer in the study group than in the controls (0.47 vs. 0.44; P < 0.005), although both groups had similar degrees of QT prolongation during drug therapy. Four of 13 patients (31 percent) who underwent multiple trials of antiarrhythmic drugs had recurrent episodes of ventricular fibrillation. Six patients died suddenly after a mean follow-up of 18 months - four who were receiving antiarrhythmic therapy and two who were not. We conclude that drug-associated ventricular fibrillation is an early event, that there may be an increased risk of its recurrence with subsequent trials of antiarrhythmic drugs, and that left ventricular dysfunction and concomitant therapy with digitalis and diuretic agents may predispose patients to this complication.

UR - http://www.scopus.com/inward/record.url?scp=0023771016&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023771016&partnerID=8YFLogxK

M3 - Article

C2 - 3393179

AN - SCOPUS:0023771016

VL - 319

SP - 257

EP - 262

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 5

ER -